Firefly Neuroscience, Inc. is an artificial intelligence (AI) technology company, which engages in developing neuroscientific solutions for mental illnesses and neurological disorders. The company is headquartered in Kenmore, New York and currently employs 17 full-time employees. The firm's BNA Platform and Evoke System are Class II medical devices, which were cleared by FDA for commercialization. The firm's FDA-510(k) cleared Evoke System, commercially deployed as the Evoke System, is in active use over 85 clinical sites in the United States. The firm has developed Firefly Platform, a vertically integrated hardware, software, and data infrastructure that captures standardized electroencephalographic (EEG) and event-related potential (ERP) assessments at the point of care, analyzes that data through its proprietary analytics engine, and delivers structured, clinician-ready reports back to the provider, all within a single seamless workflow. Its proprietary analytics engine analyzes raw EEG and ERP signals across captured dimensions and compares each patient’s electrophysiological profile to a reference dataset.
AIFF stock price ended at $1.33 on 月曜日, after dropping 2.92%
On the latest trading day Jun 22, 2026, the stock price of AIFF fell by 2.92%, dropping from $1.35 to $1.33. During the session, the stock saw a volatility of 9.23%, with prices oscillating between a daily low of $1.30 and a high of $1.42. On the latest trading day, the trading volume for AIFF rose by 155.7K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 339.1K shares were traded, with a market value of approximately $20.7M.